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Case reports describe significant norovirus gastroenteritis morbidity in immunocompromised
patients. We evaluated norovirus pathogenesis in prospectively enrolled solid organ (SOT) and
hematopoietic stem cell transplant (HSCT) patients with diarrhea who presented to Texas
Children’s Hospital and submitted stool for enteric testing. Noroviruses were detected by real-time
reverse transcription polymerase chain reaction. Clinical outcomes of norovirus diarrhea and nonnorovirus diarrhea patients, matched by transplanted organ type, were compared. Norovirus
infection was identified in 25 (22%) of 116 patients, more frequently than other enteropathogens.
Fifty percent of norovirus patients experienced diarrhea lasting ≥14 days, with median duration of
12.5 days (range 1 – 324 days); 29% developed diarrhea recurrence. Fifty-five percent of
norovirus patients were hospitalized for diarrhea, with 27% requiring intensive care unit (ICU)
admission. One HSCT recipient developed pneumatosis intestinalis. Three HSCT patients expired
≤6 months of norovirus diarrhea onset. Compared to non-norovirus diarrhea patients, norovirus
patients experienced significantly more frequent ICU admission (27% vs. 0%, p = 0.02), greater

Communication: Dr. H L Koo, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, Phone 713/798-2900, Fax
713/798-0171, koo@bcm.edu.
A preliminary version of data included in this manuscript was presented as oral abstract presentations at the IDWeek 2014 Meeting,
Philadelphia, October 10, 2014 and at the Fifth International Conference on Caliciviruses, Beijing, China, October 13, 2013.
Disclosure: The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of
Transplantation.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
Table S1. Hematopoietic Stem Cell Transplant Recipients with Norovirus (NoV) Diarrhea
Table S2. Solid Organ Transplant Recipients with Norovirus (NoV) Diarrhea

Ye et al.

Page 2

Author Manuscript

serum creatinine rise (median 0.3 vs. 0.2 mg/dL, p = 0.01), and more weight loss (median 1.6 vs.
0.6 kg, p < 0.01). Noroviruses are an important cause of diarrhea in pediatric transplant patients
and are associated with significant clinical complications.

Keywords
norovirus; diarrhea; transplant; children; solid organ transplantation; hematopoietic stem cell
transplantation

Introduction

Author Manuscript

Noroviruses (NoVs) are the most common cause of foodborne disease and acute nonbacterial gastroenteritis in the US and worldwide. In the US, approximately 19–21 million
cases of NoV infection occur each year (1). NoV gastroenteritis contributes to ~70,000
hospitalizations (1) and is the second most common cause of US gastroenteritis-related
mortality, leading to ~800 deaths annually, particularly among the elderly and infants (2).
With the success of the rotavirus vaccine, NoVs have emerged as the leading cause of US
healthcare visits for acute gastroenteritis in immunocompetent children (3). Genogroup I
(GI) and II (GII) NoVs are the most common NoV genetic groups causing gastroenteritis in
humans. The GII.4 genotype predominates worldwide (4); however, geographic and
temporal variation in NoV genotype frequency may be observed (5).

Author Manuscript

Diarrhea is commonly experienced among both solid organ (SOT) and hematopoietic stem
cell transplant (HSCT) patients, occurring in up to 90% of transplant patients (6–9).
Mortality rates of up to 55% have been associated with infectious diarrhea in these
immunocompromised patients (10). Up to 60% of diarrheal episodes in transplant recipients
have no specific etiology identified (10, 11).

Author Manuscript

NoVs represent a potentially important, underestimated enteric pathogen in the
immunocompromised transplant population. Lack of clinical suspicion of NoVs as a cause
of diarrhea and of available, sensitive molecular diagnostics at healthcare institutions has
likely led to a significant underestimation of NoV epidemiology, particularly among
immunocompromised patients. However, increasing NoV case reports among SOT and
HSCT patients suggest that NoV infection may cause significant morbidity in these patient
populations (12–15). These studies highlight the need to examine NoV infection as a cause
of diarrhea in immunocompromised patients. We conducted a prospectively enrolled,
epidemiologic surveillance study to evaluate the prevalence and clinical significance of
norovirus diarrhea among pediatric transplant recipients at Texas Children’s Hospital (TCH)
in Houston, Texas. TCH is one of the largest US children’s hospitals and has one of the most
active pediatric SOT and HSCT programs worldwide, performing approximately 100 SOTs
and over 100 HSCTs each year. We have previously demonstrated that NoVs are the most
commonly recognized enteric pathogen in the TCH general pediatric population (16).
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Materials and Methods
Study Population
Pediatric SOT and HSCT recipients with diarrhea, presenting as outpatients or admitted to
TCH and who submitted a stool specimen to the TCH microbiology laboratory for
enteropathogen testing, were screened for enrollment. Subjects who met the definition of
diarrhea were prospectively enrolled. Clinical information was collected by reviewing
medical records. The Baylor College of Medicine Institutional Review Board approved the
study protocol (protocol number: H-31513).
Definitions

Author Manuscript

Diarrhea was defined as a change in bowel habits with passage of ≥3 unformed stools within
a 24-hour period or medical documentation of diarrhea by the treating healthcare provider.
Diarrhea resolution was considered as a ≥48 hour period during which no unformed stools
were passed (17). Diarrhea recurrence was defined as a recurrent diarrhea episode occurring
>1 week after but ≤4 weeks of diarrhea resolution. Subjects who experienced diarrhea
resolution, but developed a diarrhea relapse ≤1 week afterwards were considered to have
continuation of their original diarrhea episode. Persistent diarrhea was defined as diarrhea
duration ≥14 days (18). Diarrhea with onset in the community or ≤48 hours after hospital
admission was described as community-associated diarrhea. Onset of diarrhea >48 hours
after hospital admission was considered as healthcare-associated diarrhea (19).
Norovirus detection

Author Manuscript

Stool specimens from all subjects were tested for noroviruses upon enrollment. Subsequent
stools collected at the discretion of the patient’s healthcare provider and received ≥14 days
after a previously collected stool were also tested. Viral RNA was extracted from a 10%
stool suspension in 0.01 M PBS using the QIAamp Viral RNA kit (QIAGEN) according to
the manufacturer’s directions. GI and GII NoV-positive and NoV-negative control stools
were included in each RNA extraction experiment. RNA extracts were kept at −80°C prior
to use.

Author Manuscript

Viral RNA extracts were amplified in a duplex, real-time (TaqMan®) reverse transcription
polymerase chain reaction (RT-PCR), using the AgPath-ID™ One-Step RT-PCR Kit
(Applied Biosystems). Each 25 µL real-time RT-PCR reaction mixture consisted of 3 µL of
RNA template, 400 nM of each primer (COG1F and COG1R for GI NoVs, COG2F and
COG2R for GII NoVs), and 200 nM of probe (RING1c and RING2 for GI and GII NoVs,
respectively; Table 1) (20). Real-time RT-PCR amplification was performed with a StepOne
ABI Real Time PCR system (Applied Biosystems): cDNA synthesis at 45°C for 10 min,
DNA denaturation at 95°C for 10 min, followed by 45 cycles of 95°C for 15 sec to melt
DNA and 60°C for 60 sec to anneal and extend primers. In each run, GI.1 Norwalk and GII.
4 HOV 2009 RNA transcripts were used as controls and to generate GI and GII-specific
standard curves by 10-fold serial dilutions (106 to 102 genome copies) of purified NoV GI
and GII RNA transcripts, respectively. GI.1 Norwalk and GII.4 HOV 2009 RNA transcripts
were in vitro transcribed by using pCR2.1 TOPO plasmid (Invitrogen) and pGEM-11z
plasmid (Promega Corporation), respectively. RNA transcripts were aliquoted into 0.5 ml
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tubes and stored at −80°C prior to use. The detection limit for the real-time RT-PCR assay is
100 GI or GII NoV genomic copies, which has been established by testing 10-fold serial
dilutions of the transcribed RNAs.
Norovirus Genotyping

Author Manuscript

NoV genotypes were identified through sequence analysis of PCR amplicons from all NoVpositive stools. Conventional RT-PCR was performed to sequence real-time RT-PCRpositive specimens. Briefly, 3 µL of viral RNA was amplified using 400 nM of each
oligonucleotide primer (G1SKF, G1SKR and G2SKF, G2SKR for GI and GII NoVs,
respectively) and the AgPath-ID™ One-Step RT-PCR Kit (Applied Biosystems) in a final
25 µL reaction volume. After 10 min of reverse transcription at 45°C, followed by heat
activation of Taq polymerase for 10 min at 95°C, PCR was carried out using 40 cycles at
94°C for 30 sec, 50°C for 30 sec, and 72°C for 60 sec followed by final extension for 5 min
at 72°C. RT-PCR products of the expected size were extracted after gel electrophoresis and
purified with the QIAquick Gel Extraction Kit (QIAGEN) according to the manufacturer’s
protocols. PCR products were sequenced by Genewiz, Inc. Nucleotide sequences were
compared with reference strain sequences to determine genotypes (21).
TCH Stool Microbiology Studies
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Stool microbiology studies for other enteric pathogens were performed at the treating
physician’s discretion. Clostridium difficile was detected by a real-time PCR assay
amplifying toxin A (tcdA) and B (tcdB) genes (22). A membrane-based immunogold assay
was used as the initial rotavirus assay with secondary electron microscopy (EM) analysis on
rotavirus-negative samples from January 1st to May 31st of each year. EM was used alone
for rotavirus and adenovirus identification throughout the remaining year. Adenovirus was
also detected by quantitative real-time PCR. Cytomegalovirus (CMV) screening was
performed by quantitative real-time PCR of plasma specimens and qualitative real-time PCR
of fecal samples (Viracor-IBT Laboratories). Immunofluorescence assay for CMV
antigenemia in peripheral blood leukocytes was available upon request. Stool samples were
screened for enteric bacterial pathogens, including Salmonella sp., Shigella sp., Yersinia sp.,
Campylobacter jejuni, Aeromonas sp., and Plesiomonas sp. by selective media (23). Shigatoxin producing Escherichia coli (STEC) were detected by inoculating the stool in
MacConkey broth (Remel), followed by stx1 and stx2 toxin-specific enzyme immunoassay
(Premier EHEC, Meridian Bioscience, Inc.). An EIA was performed for Cryptosporidium
sp. and Giardia sp. detection (ImmunoCard STAT, Meridian Bioscience, Inc.). Stool
examination for ova and parasites was performed by microscopy (ARUP Laboratories).
Beginning in January 2013, a multiplex nucleic acid amplification assay using Luminex®
xTag® technology became available for detecting Campylobacter sp., C.difficile toxins A
and B, Cryptosporidium sp., E. coli O157, Enterotoxigenic E. coli (LT/ST), STEC stx1/stx2,
Giardia lamblia, GI and GII NoVs, rotavirus A, Salmonella sp., and Shigella sp. (xTAG®
Gastrointestinal Pathogen Panel, Viracor-IBT Laboratories, Inc.).

Am J Transplant. Author manuscript; available in PMC 2016 July 01.
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Clinical characteristics and outcomes of subjects experiencing first NoV diarrhea episodes
were compared to non-NoV diarrhea subjects, who were systematically selected as the first
NoV-negative subject with a matching organ transplant type enrolled after a NoV diarrhea
subject was identified. Subjects receiving any tube feeding after enrollment, including those
receiving chronic enteral nutrition, were included in the epidemiologic surveillance for NoV
diarrhea in transplant patients, but were excluded from the matched case-control and viral
load analyses because tube feeding can potentially cause diarrhea. NoV and non-NoV
diarrhea patients identified with alternative enteropathogens were included in the matched
case-control comparison. NoV viral load was correlated with continuous variable host
characteristics and outcomes by Spearman correlation coefficient. Significant proportional
differences were evaluated with chi-square analysis for categorical variables. Continuous
variables were compared by Wilcoxon ranksum test. Statistical analyses were conducted
using SAS (version 9.1) software.

Results
One hundred sixteen transplant recipients, including 61 SOT and 55 HSCT patients, were
enrolled from December 1, 2012 to September 1, 2013. The mean age (± SD) of the
transplant recipients was 9 ± 6.8 years, and 55% of subjects were male. Forty-percent of
subjects were of Hispanic ethnicity, 78% of Caucasian race. The average duration from date
of transplantation to enrollment (± SD) was 433 ± 879.4 days; 126 ± 302.2 days for HSCT
patients and 734.3 ± 1,127.1 days for SOT patients (p<0.01).

Author Manuscript

Noroviruses were detected in 25 (22%) of the transplant patients with diarrhea (n=116),
including 9 SOT and 16 HSCT patients (Tables S1 and S2). NoVs were identified more
frequently than any other enteric pathogen, even when the number of tests performed for
each enteropathogen was taken into consideration (Table 2). Other diarrheal pathogens
included adenovirus (12%), C. difficile (7%), rotavirus (3%), Salmonella sp. (2%), and
Cryptosporidium sp. (1%). Co-pathogens were identified among five NoV patients,
including rotavirus (n=2), C. difficile (n=1), adenovirus (n=1), and both C. difficile and
adenovirus (n=1). Alternative enteropathogens were detected in 22 NoV-negative patients.
Three of 18 (17%) NoV patients screened positive for cytomegalovirus (CMV) viremia, but
none had confirmation of gastrointestinal invasive disease by histopathology. The majority
(76%) of NoV diarrhea cases were community-associated, while 24% were healthcareassociated.

Author Manuscript

All NoV strains were identified as GII NoVs. NoV genotypes were successfully determined
for 19 patients and included GII.4 (n=12), GII.3 (n=4), GII.6 (n=3), GII.7 (n=1), and GII.2
(n=1) strains (Figure). NoV genotypes, different from the original strain and confirmed by
repeated sequencing, were detected in two transplant patients during their diarrheal episode.
One GII.6 NoV patient was later infected with a GII.3 strain. The second patient was
positive for a GII.4 NoV strain twice over two months, followed by a GII.3 strain ~four
months later, and then the original GII.4 NoV strain one month afterwards. Based on
sequence analysis, GII.4 co-infection of the GII.3 strain in this patient cannot be excluded,
but further confirmation by cloning and NoV capsid sequencing is necessary (24).
Am J Transplant. Author manuscript; available in PMC 2016 July 01.
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Fifty percent of transplant recipients with NoV diarrhea experienced persistent diarrhea
lasting ≥14 days, and the median duration of NoV diarrhea was 12.5 days (range 1 – 324
days) (Table 3). The median maximum number of stools passed in a 24-hour period was 9
stools (range 3 – 16 stools). Approximately 30% of NoV diarrhea patients developed
recurrent diarrhea within one month of NoV diarrhea resolution. Fifty-five percent of NoV
patients were hospitalized for their diarrhea; 27% of these patients required intensive care
unit (ICU) admission during their diarrhea. Precipitating events requiring ICU admission
among NoV diarrhea patients included severe dehydration and hypovolemia from
uncontrolled diarrhea (n=2), respiratory distress (n=2), septic shock (n=1), and cardiac
arrhythmia (n=1). Three HSCT patients expired ≤6 months of NoV diarrhea onset. Two
deaths were secondary to sepsis; one death was related to pulmonary hemorrhage. One
patient suffered chronic diarrhea for >300 days, which continued until his death. Diarrhea
persistence contributed to his steady physical decline and required prolonged parenteral
nutrition, which ultimately led to fatal septic complications. NoV shedding was detected in
this patient’s stools for 238 days, after which no further stools were available for testing.
The patient died approximately 3 months after the last NoV-positive stool. Gastrointestinal
graft-versus-host disease (GVHD) and tube feeding may have also contributed to his chronic
diarrhea. Bloody stools were noted in 1 HSCT and 2 SOT patients and pneumatosis
intestinalis in 1 HSCT patient; NoVs were the only enteropathogen identified in these
patients. One additional HSCT patient developed bloody diarrhea, but was also positive for
adenovirus.

Author Manuscript

To compare host characteristics and diarrhea severity between NoV diarrhea and non-NoV
diarrhea transplant recipients, we performed a matched case-control analysis of NoV
diarrhea subjects (n=22) and non-NoV diarrhea subjects (n=22), after excluding 3 NoVpositive subjects (2 HSCT and 1 SOT patients) who received tube feeding. NoV diarrhea
patients were significantly more frequently admitted to the ICU during their diarrhea (27%
vs. 0%, p = 0.02), experienced a greater rise in serum creatinine (median 0.3 vs. 0.2 mg/dL,
p = 0.01), and lost more weight (median 1.6 vs. 0.6 kg, p < 0.01) than non-NoV diarrhea
patients. NoV diarrhea patients were also more frequently admitted to the hospital for
diarrhea, experienced greater diarrhea persistence, and passed more stools within a 24-hour
period than non-NoV diarrhea patients; however, these differences were not statistically
significant.

Author Manuscript

Three (14%; 3 HSCT) patients developed NoV diarrhea prior to transplantation (1–3 days),
2 (9%; 2 HSCT) <1 month after transplantation, 6 (27%; 5 HSCT, 1 SOT) 1–6 months after
transplantation, and 11 (50%; 4 HSCT, 7 SOT) >6 months after transplantation. Onset of
non-NoV diarrhea in relation to transplantation, including more frequent diarrhea in the late
post-transplantation period for SOT than HSCT patients, was similarly distributed.
NoV diarrhea was more prevalent among HSCT patients (30%) than in SOT patients (13%,
p = 0.03). NoV HSCT patients were significantly younger (mean ± SD, 8.3 ± 5.7 vs. 14.2 ±
5.5 years, p = 0.02) and more likely to experience diarrhea recurrence (46% vs. 0%, p <0.05)
than NoV SOT patients. Graft-versus-host disease (GVHD) was present in 8 HSCT patients
with NoV diarrhea, including 3 recipients with gastrointestinal GVHD. Two patients were
diagnosed endoscopically with gut GVHD during their diarrheal episode and received
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increased immunosuppression; however, their diarrhea was refractory and persisted for 98 –
301 days. One patient with a past history of gastrointestinal GVHD developed diarrhea,
which was attributed to NoV gastroenteritis. CMV viremia (range 200 – 5,200 copies/mL)
was detected in 3 NoV HSCT patients. Two of these patients received either ganciclovir or
valganciclovir for viremia; however, CMV infection was not deemed as contributing to the
diarrhea by the treating physicians. No significant differences in NoV diarrhea severity,
regarding duration, number of diarrheal stools, associated complications including hospital
or ICU admission, or laboratory abnormalities between the two transplant groups were
observed (data not shown).

Author Manuscript

The mean NoV viral load was 6.3 × 108 genomic copies per gram of stool among NoV
diarrhea patients. NoV fecal load was similar between HSCT and SOT patients (mean 7.4 ×
108 vs. 4.3 × 108 genomic copies per gram of stool, p = 0.68). Fifteen of the twenty-five
NoV diarrhea subjects (60%) provided ≥1 additional stool samples collected ≥14 days apart.
Nine (60%) of these NoV diarrhea patients were persistently positive, with median NoV
shedding duration of 31 days (range 14 – 238 days). Three subjects continued to shed NoVs
asymptomatically after diarrhea resolution, ranging from 10 – 91 days. Greater NoV load
was significantly correlated with increased maximal number of stools in a 24-hour period (rs
= 0.50, p = 0.03). No correlation was observed between NoV shedding and other measures
of diarrhea severity (duration), complications (fever, renal insufficiency, weight loss,
hospital or ICU requirement), or host absolute lymphocyte count at diarrhea onset (data not
shown).

Discussion
Author Manuscript

SOT and HSCT recipients are at high risk for developing infections because of their
significant immunosuppression related to their underlying disease, immunosuppressive
therapy for organ engraftment and prevention of organ rejection, delayed immune recovery
following transplantation, and complications such as graft-versus-host disease (25). Humoral
and cell-mediated immunosuppression likely render SOT and HSCT recipients susceptible
to NoV infection and severe disease and impair their ability to clear NoV infection.

Author Manuscript

Case reports and small, retrospective studies have described severe, prolonged NoV disease
among immunocompromised hosts complicated by fever, recurrent hospitalizations for
dehydration (26), chronic diarrhea persisting months to years (12), acute renal failure
requiring hemodialysis (13, 14), weight loss, malnutrition requiring supplemental enteral or
parenteral nutrition (13), enteritis (15), pneumatosis intestinalis (27), peritonitis (15),
impaired mucosal barrier function with secondary bacteremia (15, 28), and death (12, 15).
However, these studies were primarily anecdotal and included relatively few transplant
patients. We conducted a large, prospectively enrolled surveillance study in an attempt to
better define the epidemiologic and clinical significance of NoV diarrhea among pediatric
transplant recipients.
Overall NoV prevalence was 22% among pediatric transplant recipients with diarrhea. NoVs
were the most common enteric pathogen identified, almost as common as all other
enteropathogens collectively. The majority of NoV diarrhea cases were associated with the
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community, but approximately 25% of patients were diagnosed with NoV infection in the
healthcare setting. NoV diarrhea was often severe in these children, lasting on average >1
month, requiring frequent hospitalization for uncontrolled diarrhea, and was associated with
dehydration and malnutrition complications and ICU admission. Four NoV diarrhea
patients, including two patients excluded from the matched case-control analysis for receipt
of tube feeding, required ICU admission for complications from severe diarrhea. One patient
developed pneumatosis intestinalis. Three NoV patients died within 6 months of NoV
diagnosis, including one death related to persistent diarrhea.

Author Manuscript

Establishing the etiology of diarrhea in immunocompromised hosts is challenging, with a
myriad of potential causes including medications such as immunosuppressants and
antibiotics, infection, chronic gastrointestinal disorders, immune phenomenon such as
allograft rejection and GVHD, post-transplantation lymphoproliferative disease in SOT
patients, and mucositis secondary to conditioning regimens in HSCT recipients (29–31). In
addition, asymptomatic NoV infection has been described in up to one-third of healthy
persons exposed to NoVs (32). Asymptomatic NoV prevalence among
immunocompromised individuals is unknown. In our study, NoV diarrhea transplant
patients required significantly more frequent ICU admission and experienced greater renal
insufficiency and weight loss than non-NoV diarrhea patients. Worse renal insufficiency in
NoV patients likely resulted from significant diarrhea-related dehydration. These adverse
clinical outcomes associated with NoV diarrhea support the pathogenic role of NoV
infection in these transplant recipients.
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Distinguishing NoV disease from asymptomatic infection based on higher NoV loads has
been proposed (33). However, the majority of studies evaluating the association between
NoV fecal concentrations and clinical manifestations comprised immunocompetent hosts
and reported conflicting results (17, 34, 35). Higher NoV fecal loads were associated with
increased diarrheal stools in a 24-hour period in our transplant cohort, but did not correlate
with other diarrhea severity markers. NoV shedding persisted a median of 31 days and up to
238 days. Future systematic collection and testing of stools from NoV-positive patients
needs to be performed to more precisely assess NoV persistence in transplant patients.
Chronic NoV shedding may have contributed to nosocomial acquisition of NoV infection,
leading to the significant proportion of healthcare-associated NoV cases. However,
additional epidemiologic and NoV sequencing studies are needed to confirm nosocomial
transmission in our transplant patient cohort. Optimal infection control measures for
persistent immunocompromised NoV shedders need to be established. These chronic NoVinfected hosts may also represent a reservoir for the emergence of new epidemic strains after
accelerated NoV genomic evolution (36).

Author Manuscript

SOT patients usually experience maximal immunosuppression 1 – 6 months after
transplantation. Allogeneic HSCT recipients may undergo even more profound
immunosuppression with myeloablative regimens, which eradicate the recipient’s
lymphohematopoietic system in preparation for donor stem cell transfer. In our study, HSCT
patients presented with diarrhea earlier after transplantation than SOT patients, which likely
reflects this severe immunosuppression prior to stem cell engraftment. In our matched casecontrol cohort, HSCT recipients also had significantly lower median white blood cell (2.6
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vs. 9.1 cells/µL, p < 0.01) and median absolute lymphocyte counts (279 vs. 1,035 cells/µL, p
< 0.01) than SOT patients. In addition, 8 HSCT patients had GVHD. Greater
immunosuppression among HSCT patients likely led to significantly higher NoV diarrhea
prevalence and recurrence in HSCT patients compared to SOT subjects.

Author Manuscript

Study limitations include the passive enrollment and surveillance of subjects. Only subjects
who submitted stool samples to the TCH microbiology laboratory and experienced diarrhea
were enrolled. Another study limitation was the collection of clinical information from
medical records. Stool frequency and form were well-documented in hospital records for
patients admitted to the hospital, but more variable for outpatients. Although this study only
enrolled transplant patients with diarrhea, a minority of patients (n=9) began having diarrhea
symptoms prior to their transplantation. These patients were included, as previously
published case reports have described significant NoV morbidity in HSCT patients who
acquired NoV infection prior to their HSCT (9, 37). An additional study limitation was the
inclusion of NoV-positive and – negative subjects identified with other diarrheal pathogens
in our matched case-control comparison of NoV-diarrhea and non-NoV diarrhea subjects.
Subjects with co-pathogens were not excluded to avoid potentially underpowering our
analysis, given the relatively small number of subjects. While these other diarrheal
pathogens may have contributed to clinical outcomes attributed to NoVs, non-NoV diarrhea
subjects with co-pathogens were also included. Finally, we cannot exclude that transplant
patients with NoV infection may have developed diarrhea due to other causes. However, the
worse clinical outcomes observed with NoV diarrhea support the pathogenic role of
noroviruses in these immunocompromised patients.
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Noroviruses are an important cause of diarrhea and are associated with significant
complications in immunocompromised pediatric transplant recipients. However, studies are
urgently needed to further define NoV pathogenesis in transplant recipients. Establishing
NoVs as the causative diarrheal agent in a timely manner is critical to improving clinical
management and limiting unwarranted adverse effects from antibiotics for possible bacterial
diarrhea; invasive, endoscopic procedures to diagnose GVHD; and inappropriate escalation
of immunosuppression for presumed gastrointestinal GVHD rather than reduction to control
NoV infection. Immunocompromised transplant patients represent an important population
susceptible to norovirus diarrhea, who may benefit from future novel therapeutic and
preventative strategies such as immunoglobulin therapy (38), including monoclonal
antibodies (39), or norovirus antivirals or vaccines (40).
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Refer to Web version on PubMed Central for supplementary material.
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NoV

norovirus

SOT

solid organ transplantation

HSCT

hematopoietic stem cell transplantation

GI

genogroup I

GII

genogroup II

ICU

intensive care unit

TCH

Texas Children’s Hospital

RT-PCR

reverse transcription polymerase chain reaction

EM

electron microscopy

STEC

Shiga-toxin producing Escherichia coli

CMV

cytomegalovirus

GVHD

graft-versus-host disease
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Figure.

Norovirus Genotypes Identified
Note. Phylogenetic analysis of genogroup II (GII) norovirus (NoV) strains identified from
pediatric transplant recipients based on partial nucleotide sequences of the NoV capsid gene.
The dendogram was constructed by the maximum likelihood method using the software
MEGA 6.0. A Kimura 2-parameter model was used for nucleotide substitution; substitution
rates were assumed to be gamma distributed. Study samples are listed by subject number,
sample number (e.g., 6.1); location (TCH, Texas Children’s Hospital), month (for patients
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with NoV detection on more than one occasion), and year of collection. Percentage
bootstrap values are shown at the branch nodes. The scale indicates nucleotide substitutions
per site. Subjects 6 and 10 were positive for different GII NoV genotypes during their
diarrheal episode.
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Table 1

Author Manuscript

Primer and probe sequences for conventional (NoV genotyping) and real-time RT-PCR (NoV detection)
Purpose

GI detection

GII detection

Primer/probe

Sequence (5′–3′)

COG IF

CGYTGGATGCGITTYCATGA

COG IR

CTTAGACGCCATCATCATTYAC

Ring 1C

FAM - AGATYGCGITCICCTGTCCA - BHQ

COG 2F

CARGARBCNATGTTYAGRTGGATGAG

COG 2R

TCGACGCCATCTTCATTCACA

Ring 2

JOE - TGGGAGGGCGATCGCAATCT - BHQ

G1SKF

CTGCCCGAATTYGTAAATGA

G1SKR

CCAACCCARCCATTRTACA

G2SKF

CNTGGGAGGGCGATCGCAA

G2SKR

CCRCCNGCATRHCCRTTRTACAT

GI genotyping

Amplicon
size (bp)

85

98

330

Author Manuscript

GII genotyping

344

Note: FAM, 6-carboxyfluorescein; BHQ, Black Hole Quencher; JOE, 2,7 dimethoxy-4,5-dichloro-6-carboxyfluorescein.
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Table 2

Author Manuscript

Enteric Pathogen Prevalence in Transplant Recipients (n=116)
Enteric Pathogen

Prevalence
(% Total Subjects)

No. Tests Performed
(% Positive)

Norovirus

25 (22)

116 (22)

Author Manuscript

Adenovirus

14 (12)

71 (20)

Clostridium difficile

8 (7)

92 (9)

Rotavirus

3 (3)

60 (5)

Salmonella sp.

2 (2)

96 (2)

Cryptosporidium sp.

1 (1)

58 (2)

Giardia sp.

0

58 (0)

Shigella sp.

0

96 (0)

Campylobacter sp.

0

96 (0)

STEC*

0

96 (0)

Yersinia sp.

0

96 (0)

Note.
Abbreviation: STEC, Shiga-toxin producing Escherichia coli
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Table 3

Author Manuscript

Characteristics of Transplant Recipients with Norovirus (NoV) Diarrhea and non-NoV Diarrhea*
NoV Diarrhea
(n=22)

non-NoV Diarrhea
(n=22)

P-value

10.4 ± 6.2

9.3 ± 7.2

0.49

11 (50)

7 (32)

0.22

  Median

136.5

93

0.77

  Range

−3 to 1962

−5 to 4079

12 (55)

8 (36)

0.23

Age, mean years ± SD
Female patient (%)
Duration from transplantation to diarrhea onset (days)

Hospital admission for diarrhea (%)
Intensive care unit admission during diarrhea episode (%)

Author Manuscript

6 (27)

0

0.02

Median white blood cell count (cells/uL) (range)‡

4.3 (0–14.1)

4.1 (0–11.8)

0.72

Median absolute lymphocyte count (cells/uL) (range)‡

777 (0–6453)

392 (0–2068)

0.59

7 (32)

8 (36)

0.75

12.5 (1–324)

7 (1–34)

0.16

Persistent diarrhea** (%)

11 (50)

8 (36)

0.36

Recurrence of diarrhea†

6 (29)

7 (33)

0.74

9 (3–16)

8 (3–14)

0.16

0.3 (0–1.4)

0.2 (0–0.9)

0.01

1.6 (0–7)

0.6 (0–3.8)

<0.01

Presence of fever at diarrhea onset (%)
Median duration of diarrhea (range)

Median maximum no. stool in 24 hours (range)
Median rise in serum creatinine (mg/dL) during diarrhea (range)
Median weight loss (kg) during diarrhea (range)
Required total parenteral nutrition during diarrhea (%)

12 (55)

8 (37)

0.23

Death during diarrhea episode (%)

1 (5)

0

1.00

Death within 6 months of diarrhea onset (%)

2 (9)

1 (5)

1.00

Author Manuscript

Note:
*

Transplant patients receiving tube feeding were excluded, including 3 NoV diarrhea subjects, one of whom expired ≤6 months of diarrhea onset.
Five NoV diarrhea patients were co-infected with C. difficile (n=2), rotavirus (n=2), or adenovirus (n=2). Four non-NoV diarrhea patients were
identified with C. difficile (n=2) or adenovirus (n=2).
‡

Within 24 hours of diarrhea onset.

**

Persistent diarrhea was defined as diarrhea duration ≥14 days.

†

Recurrence of diarrhea >1 week but ≤4 weeks of diarrhea resolution. Data for diarrhea recurrence was not available for 1 NoV and 1 non-NoV
patient.
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